Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction

Journal of Cardiology

Volumn 53, Issue 2, 2009, Pages 171-178

  Kawamura, Akihiro ^a   Yuasa, Fumio ^a   Yokoe, Hiroshi ^a   Masue, Yoh ^a   Sugiura, Tetsuro ^b   Iwasaka, Toshiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Arterial baroreflex sensitivity; Cardiopulmonary baroreflex sensitivity; Sympathetic nerve activity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PHENYLEPHRINE; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; MALE; NERVE POTENTIAL; PRESSORECEPTOR REFLEX; SYMPATHETIC NERVE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIES; BAROREFLEX; DRUG SYNERGISM; ENALAPRIL; FEMALE; HEART; HEMODYNAMICS; HUMANS; LUNG; MALE; MIDDLE AGED; SYMPATHETIC NERVOUS SYSTEM; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 62349106234     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2008.09.016     Document Type: Article

References (27)

1. Abbound F.M., Thames M.D., and Mark A.L. Role of cardiac afferent nerves in regulation of circulation during coronary occlusion and heart failure. In: Abbound F.M., Fozzard H.A., Gilmore J.P., and Reis D.J. (Eds). Disturbances in neurogenic control of the circulation (1981), American Physiological Society, Bethesda, MD 65-86
2. Ferguson D.W., Berg W.J., Roach P.J., Oren R.M., and Mark A.L. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol 69 (1992) 523-531
3. Grassi G., Seravalle G., Cattaneo B.M., Lanfranchi A., Vailati S., Giannattasio C., et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 92 (1995) 3206-3211
4. Sander-Jensen K., Secher N.H., Astrup A., Christensen N.J., Damkjaer-Nielsen M., Giese J., et al. Angiotensin II attenuates reflex decrease in heart rate and sympathetic activity in man. Clin Physiol 8 (1988) 31-40
5. Barron K.W., Trapani A.J., Gordon F.J., and Brody M.J. Baroreceptor denervation profoundly enhances cardiovascular responses to central angiotensin II. Am J Physiol 257 (1989) H314-323
6. Berenguer L.M., Garcia-Estan J., Ubeda M., Ortiz A.J., and Quesada T. Role of renin-angiotensin system in the impairment of baroreflex control heart rate in renal hypertension. J Hypertens 9 (1991) 1127-1133
7. Dibner-Dunlap M.E., Smith M.L., Kinugawa T., and Thames M.D. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J Am Coll Cardiol 27 (1996) 358-364
8. Grassi G., Cattaneo B.M., Seravelle G., Lanfranchi A., Pozzi M., Morganti A., et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 96 (1997) 1173-1179
9. Juillerat L., Nussberger J., and Menard J. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16 (1990) 564-572
10. Urata H., Nishimura H., and Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens 9 (1996) 277-284
11. Minisi A.J., and Thames M.D. Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circulation 87 (1993) 240-246
12. Hikosaka M., Yuasa F., Yuyama R., Mimura J., Kawamura A., Motohiro M., et al. Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure. J Cardiovasc Pharmacol 40 (2002) 875-880
13. Voelker J.R., Cobb S.L., and Bowsher R.R. Improved HPLC-radioimmunoassay for quantifying angiotensin II in plasma. Clin Chem 40 (1994) 1537-1543
14. Shibasaki Y., Mori Y., Tsutumi Y., Masaki H., Sakamoto K., Murasawa S., et al. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 51 (1999) 83-91
15. Eckberg D.L., Drabinsky M., and Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 285 (1971) 877-883
16. Wang W., Chen J.S., and Zucker I.H. Carotid sinus baroreceptor sensitivity in experimental heart failure. Circulation 81 (1990) 1959-1966
17. Mohanty P.K., Arrowood J.A., Ellenbogen K.A., and Thames M.D. Neurohumoral and hemodynamics effects of lower body negative pressure in patients congestive heart failure. Am Heart J 118 (1989) 78-85
18. Ferguson D.W., Abboud F.M., and Mark A.L. Selective impairment of baroreflex mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 69 (1984) 451-460
19. Murakami H., Liu J.L., and Zucker I.H. Blockade of AT1 receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am J Physiol 271 (1996) R303-R309
20. Nishizawa M., Kumagai M., Ichikawa N., Oshima N., Suzuki H., and Saruta T. Improvement in baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction. Hypertension 29 (1997) 458-463
21. Head G.A. Role of AT1 receptors in the central control of sympathetic vasomotor function. Clin Exp Pharmacol Physiol Suppl 3 (1996) S93-98
22. Unger T., Chung O., and Csikos T. Angiotensin receptors. J Hypertens Suppl 14 (1996) S95-S103
23. Brasch H., Sierslawski L., and Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 22 (1993) 699-704
24. Brooks V.L., Ell K.R., and Wright R.M. Pressure-independent baroreflex resetting produced by chronic infusion of angiotensin II in rabbits. Am J Physiol Heart Circ Physiol 265 (1993) H1275-H1282
25. Wong J., Chou L., and Reid I.A. Role of AT1 receptors in the resetting of the baroreflex control of heart rate by angiotensin II in the rabbit. J Clin Invest 91 (1993) 1516-1520
26. Baruch L., Anand I., Cohens I.S., Ziesche S., Judd D., and Cohn J.N. Augmented short and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 99 (1999) 2658-2664
27. Cohn J.N., Anand I.S., Latini R., Masson S., Chiang Y.T., Glazer R., et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 108 (2003) 1306-1309